Filtered By:
Cancer: Myeloma

This page shows you your search results in order of date. This is page number 6.

Order by Relevance | Date

Total 122 results found since Jan 2013.

GSE79820 Deptor transcriptionally regulates Endoplasmic Reticulum homeostasis in Multiple Myeloma cells.
Contributors : Valeria Catena ; Tiziana Bruno ; Francesca De Nicola ; Frauke Goeman ; Matteo Pallocca ; Simona Iezzi ; Cristina Sorino ; Giovanni Cigliana ; Aristide Floridi ; Giovanni Blandino ; Maurizio FanciulliSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensWe performed a RNA-seq analysis by using mRNA from KMS27 cells transfected with siRNA Deptor or siRNA negative control.
Source: GEO: Gene Expression Omnibus - December 27, 2016 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

Rocaglamide breaks TRAIL-resistance in human multiple myeloma and acute T-cell leukemia in vivo in a mouse xenogtraft model
Multiple myeloma (MM) is an incurable malignancy by the presently known therapies. TRAIL is a promising anticancer agent that virtually not shows any toxicity to normal cells. We have recently carried out clinical trials with a human circularly permuted TRAIL, CPT, against MM saw a partial response in approximate 20 – 30% of patients. In the current study, we investigated the cause of CPT resistance and revealed that the majority of the MM patients express elevated levels of c-FLIP. Knockdown of c-FLIP expression by siRNA alone was sufficient to increase CPT-mediated apoptosis in a CPT-resistant human MM cell line U266.
Source: Cancer Letters - December 17, 2016 Category: Cancer & Oncology Authors: Yin Wu, Marco Giaisi, Rebecca K öhler, Dr. Wen-Ming Chen, Peter H. Krammer, Dr. Min Li-Weber Tags: Original Articles Source Type: research

Rocaglamide breaks TRAIL-resistance in human multiple myeloma and acute T-cell leukemia in  vivo in a mouse xenogtraft model
Multiple myeloma (MM) is an incurable malignancy by the presently known therapies. TRAIL is a promising anticancer agent that virtually not shows any toxicity to normal cells. We have recently carried out clinical trials with a human circularly permuted TRAIL, CPT, against MM saw a partial response in approximate 20 –30% of patients. In the current study, we investigated the cause of CPT resistance and revealed that the majority of the MM patients express elevated levels of c-FLIP. Knockdown of c-FLIP expression by siRNA alone was sufficient to increase CPT-mediated apoptosis in a CPT-resistant human MM cell line U266.
Source: Cancer Letters - December 17, 2016 Category: Cancer & Oncology Authors: Yin Wu, Marco Giaisi, Rebecca K öhler, Wen-Ming Chen, Peter H. Krammer, Min Li-Weber Tags: Original Article Source Type: research

Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming.
Authors: Riz I, Hawley TS, Marsal JW, Hawley RG Abstract Multiple Myeloma (MM) is a B-cell malignancy characterized by the accumulation of clonal plasma cells in the bone marrow, with drug resistance being a major cause of therapeutic failure. We established a carfilzomib-resistant derivative of the LP-1 MM cell line (LP-1/Cfz) and found that the transcription factor NF-E2 p45-related factor 2 (Nrf2; gene symbol NFE2L2) contributes to carfilzomib resistance. The mechanism of Nrf2 activation involved enhanced translation of Nrf2 as well as its positive regulator, the autophagy receptor sequestosome 1 (SQSTM1)/p62. T...
Source: Oncotarget - September 15, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

CSTMP induces apoptosis and mitochondrial dysfunction in human myeloma RPMI8226 cells via CHOP-dependent endoplasmic reticulum stress.
CONCLUSIONS: Our results indicated that CSTMP could induce apoptosis and mitochondrial dysfunction in RPMI8226 cells via CHOP-dependent ER stress. PMID: 27490778 [PubMed - as supplied by publisher]
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 31, 2016 Category: Drugs & Pharmacology Authors: Sun X, Liao W, Wang J, Wang P, Gao H, Wang M, Xu C, Zhong Y, Ding Y Tags: Biomed Pharmacother Source Type: research

Metformin elicits antitumor effects and downregulates the histone methyltransferase multiple myeloma SET domain (MMSET) in prostate cancer cells
CONCLUSIONSThese data suggest MMSET may play a role in the inhibitory effect of metformin on PCa and could serve as a potential novel therapeutic target for PCa. Prostate © 2016 Wiley Periodicals, Inc.
Source: The Prostate - July 11, 2016 Category: Urology & Nephrology Authors: Nicole M. A. White‐Al Habeeb, Julia Garcia, Neil Fleshner, Bharati Bapat Tags: Original Article Source Type: research

Preparation of Antispermidine/Spermine-N1-Acetyltransferase Monoclonal Antibodies.
Authors: Chen Y, Zhang C Abstract Spermidine/spermine N1-acetyltransferase (SSAT) is a catabolic regulator of polyamines, ubiquitous molecules essential for cell proliferation and differentiation. Anti-SSAT antibodies (monoclonal antibodies [mAbs]) of high titer were prepared by immunizing BALB/c mice with multifocal intradermal injections and by fusing high-titer antibody-producing spleen cells with myeloma cells of SP2/0 origin. Four mAbs were selected for further characterization as classes and subclasses. Antibodies were produced by these three clones with high affinities ranging from 10(9) to 10(11) M(-1). The...
Source: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy - May 28, 2016 Category: Microbiology Tags: Monoclon Antib Immunodiagn Immunother Source Type: research

Che-1 gene silencing by inhibiting mutant p53 expression.
In this study, we aimed to investigate the effects and specific mechanism of Che-1 in the regulation of osteosarcoma (OS) cell growth. We found that Che-1 is highly expressed in several kinds of OS cells compared with osteoblast hFOB1.19 cells. MTT and flow cytometry assays showed that Che-1 depletion by siRNA markedly suppressed MG-63 and U2OS cell proliferation and promoted apoptosis. The chromatin immunoprecipitation (ChIP) assay verified the presence of Che-1 on the p53 promoter in MG-63 and U2OS cells carrying mutant p53. Further studies showed that Che-1 depletion inhibited mutant p53 expression. Notably, our study s...
Source: Biochemical and Biophysical Research communications - March 20, 2016 Category: Biochemistry Authors: Liu M, Wang D, Li N Tags: Biochem Biophys Res Commun Source Type: research

Traf2- and Nck-interacting kinase (TNIK) is involved in the anti-cancer mechanism of dovitinib in human multiple myeloma IM-9 cells.
Abstract Traf2- and Nck-interacting kinase (TNIK) is a member of the germinal center kinase family. TNIK was first identified as a kinase that is involved in regulating cytoskeletal organization in many types of cells, and it was recently proposed as a novel therapeutic target in several types of human cancers. Although previous studies suggest that TNIK plays a pivotal role in cancer cell survival and prognosis, its function in hematological cancer cell survival has not been investigated. Here we investigated the relationship between TNIK function and cell viability in multiple myeloma IM-9 cells using TNIK small...
Source: Amino Acids - March 19, 2016 Category: Biochemistry Authors: Chon HJ, Lee Y, Bae KJ, Byun BJ, Kim SA, Kim J Tags: Amino Acids Source Type: research

Reelin promotes the adhesion and drug resistance of multiple myeloma cells via integrin β1 signaling and STAT3.
Authors: Lin L, Yan F, Zhao D, Lv M, Liang X, Dai H, Qin X, Zhang Y, Hao J, Sun X, Yin Y, Huang X, Zhang J, Lu J, Ge Q Abstract Reelin is an extracellular matrix (ECM) protein that is essential for neuron migration and positioning. The expression of reelin in multiple myeloma (MM) cells and its association with cell adhesion and survival were investigated. Overexpression, siRNA knockdown, and the addition of recombinant protein of reelin were used to examine the function of reelin in MM cells. Clinically, high expression of reelin was negatively associated with progression-free survival and overall survival. Functi...
Source: Oncotarget - February 9, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Binding of B‐cell maturation antigen to B‐cell activating factor induces survival of multiple myeloma cells by activating Akt and JNK signaling pathways
In this study, we characterized the mechanism underlying the protein kinase B (Akt) and c‐Jun N‐terminal kinase (JNK) pathways and BCMA interactions in regulating multiple myeloma (MM) cell survival. It was found that the expression levels of B cell‐activating factor (BAFF) and BCMA were increased in MM cells as compared with those in normal controls. The proliferation of U266 cells was induced by recombinant human BAFF (rhBAFF) and could also be decreased by BCMA siRNA. The expression of Bcl‐2 protein was up‐regulated, and Bax protein was down‐regulated after rhBAFF treatment, which could be reversed by BCMA s...
Source: Cell Biochemistry and Function - January 1, 2016 Category: Biochemistry Authors: Xianjuan Shen, Yuehua Guo, Jing Qi, Wei Shi, Xinhua Wu, Shaoqing Ju Tags: Research Article Source Type: research

Upregulation of CCL2 via ATF3/c-Jun interaction mediated the Bortezomib-induced peripheral neuropathy
Publication date: Available online 10 November 2015 Source:Brain, Behavior, and Immunity Author(s): Cuicui Liu, Shuo Luan, Handong OuYang, Zhenzhen Huang, Shaoling Wu, Chao Ma, Jiayou Wei, Wenjun Xin Bortezomib (BTZ) is a frequently used chemotherapeutic drug for the treatment of refractory multiple myeloma and hematological neoplasms. The mechanism by which the administration of BTZ leads to painful peripheral neuropathy remains unclear. In present study, we found that application of BTZ at 0.4 mg/kg for consecutive 5 days significantly increased the expression of CCL2 in DRG, and intrathecal administration of n...
Source: Brain, Behavior, and Immunity - November 13, 2015 Category: Neurology Source Type: research

Upregulation of CCL2 via ATF3/c-Jun interaction mediated the Bortezomib-induced peripheral neuropathy.
Abstract Bortezomib (BTZ) is a frequently used chemotherapeutic drug for the treatment of refractory multiple myeloma and hematological neoplasms. The mechanism by which the administration of BTZ leads to painful peripheral neuropathy remains unclear. In present study, we found that application of BTZ at 0.4 mg/kg for consecutive 5 days significantly increased the expression of CCL2 in DRG, and intrathecal administration of neutralizing antibody against CCL2 inhibited the mechanical allodynia induced by BTZ. We also found an increased expression of c-Jun in DRG, and that inhibition of c-Jun signaling prevented the...
Source: Brain, Behavior, and Immunity - November 7, 2015 Category: Neurology Authors: Liu C, Luan S, OuYang H, Huang Z, Wu S, Ma C, Wei J, Xin W Tags: Brain Behav Immun Source Type: research

Notch Increased Vitronection Adhesion Protects myeloma cells from drug induced Apoptosis.
This study first connected Notch signaling, VTN adhesion and drug resistance together. Therefore, blocking αvβ5 receptor with antibody or knock down approach would be a novel promising strategy to treat MM. PMID: 26494298 [PubMed - as supplied by publisher]
Source: Biochemical and Biophysical Research communications - October 19, 2015 Category: Biochemistry Authors: Ding Y, Shen Y Tags: Biochem Biophys Res Commun Source Type: research

Synergistic anti‐myeloma activity of the proteasome inhibitor marizomib and the IMiD® immunomodulatory drug pomalidomide
Abstract The proteasome inhibitor bortezomib is an effective therapy for the treatment of relapsed and refractory multiple myeloma (RRMM); however, prolonged treatment can be associated with toxicity, peripheral neuropathy and drug resistance. Our earlier studies showed that the novel proteasome inhibitor marizomib is distinct from bortezomib in its chemical structure, mechanisms of action and effects on proteasomal activities, and that it can overcome bortezomib resistance. Pomalidomide, like lenalidomide, has potent immunomodulatory activity and has been approved by the US Food and Drug Administration for the treatment o...
Source: British Journal of Haematology - October 12, 2015 Category: Hematology Authors: Deepika S. Das, Arghya Ray, Yan Song, Paul Richardson, Mohit Trikha, Dharminder Chauhan, Kenneth C. Anderson Tags: Research Paper Source Type: research